Insurance navigation versus flat-rate compounding — two coherent but opposite bets on what GLP-1 buyers actually need: help unlocking coverage and brand product, or the cheapest predictable cash number.
The two models
Ro plays the insurance-navigation game better than most of the category: coverage checks, prior-authorization support, and — since its 2025 arrangement to dispense Lilly’s Zepbound vials — a direct lane to brand product at manufacturer self-pay prices. Its own fees, effective monthly totals, and compounded posture remain in our verification queue, so no Ro figure appears here yet.
Henry Meds advertises the market’s best-known flat-rate compounded pricing — a structure we favor on principle, because flat rates make teaser math impossible. Whether the advertised flat number survives contact with membership terms, shipping, and dose realities is precisely what its pending verification pass will establish; until then, no Henry figure is published here.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
Which bet fits which buyer
If you have insurance worth fighting for, Ro’s navigation-plus-brand-vials lane is structurally the right conversation — a copay or manufacturer self-pay price can beat any compounded rate. If you’re a cash buyer optimizing for predictability, Henry’s flat-rate structure is the right architecture. Both sides’ actual totals: pending verification, which is the only reason this page renders no winner.
Go deeper
Full files: Ro · Henry Meds. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.